The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
James Chih-Hsin Yang
Consultant or Advisory Role - Boehringer Ingelheim (U)
Honoraria - Boehringer Ingelheim
Martin H. Schuler
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim
Other Remuneration - Lilly
Nobuyuki Yamamoto
No relevant relationships to disclose
Kenneth John O'Byrne
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim; Lilly
Research Funding - Boehringer Ingelheim
Other Remuneration - Boehringer Ingelheim; Lilly
Vera Hirsh
Honoraria - Boehringer Ingelheim
Tony Mok
Employment or Leadership Position - Chinese University of Hong Kong
Consultant or Advisory Role - AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Honoraria - AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca
Sarayut Lucien Geater
No relevant relationships to disclose
Sergey V Orlov
No relevant relationships to disclose
Chun-Ming Tsai
No relevant relationships to disclose
Michael J. Boyer
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim; Lilly
Research Funding - Boehringer Ingelheim
Wu-Chou Su
No relevant relationships to disclose
Jaafar Bennouna
Consultant or Advisory Role - Amgen
Honoraria - Boehringer Ingelheim; Roche
Terufumi Kato
No relevant relationships to disclose
Vera Gorbunova
No relevant relationships to disclose
Ki Hyeong Lee
No relevant relationships to disclose
Riyaz N.H. Shah
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Other Remuneration - Boehringer Ingelheim
Dan Massey
Employment or Leadership Position - Boehringer Ingelheim
Robert M. Lorence
Employment or Leadership Position - Boehringer Ingelheim
Mehdi Shahidi
Employment or Leadership Position - Boehringer Ingelheim
Lecia V. Sequist
Consultant or Advisory Role - Boehringer Ingelheim (U); Celgene; Clovis Oncology; Daiichi Sankyo (U); Merrimack (U)
Research Funding - Boehringer Ingelheim